Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26041516 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Carmen Duță und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania. Hauptthemen laut MEDLINE: Ferroptosis, Parkinson Disease, Drug Repositioning, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
This review explores the promising potential of repurposing type 2 diabetes (T2D) medications for the treatment of Parkinson’s disease (PD), highlighting the shared pathophysiological mechanisms between these two age-related conditions, such as oxidative stress, mitochondrial dysfunction, and ferroptosis. The overlap suggests that existing diabetes drugs could target the common pathways involved in both conditions. Specifically, the review discusses how T2D medications, including metformin (Met), peroxisome-proliferator-activated receptor gamma (PPAR-γ) agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, incretins, and dipeptidyl-peptidase 4 (DPP-4) inhibitors, can improve mitochondrial function, reduce neuroinflammation and oxidative stress, and potentially inhibit ferroptosis. The connection between ferroptosis and existing treatments, including diabetes medication, are only beginning to be explored. The limited data can be attributed also to the complexity of mechanisms involved in ferroptosis and Parkinson’s disease and to the fact that the specific role of ferroptosis in Parkinson’s disease pathogenesis has not been a primary focus until recent. Despite the promising preclinical evidence, clinical findings are mixed, underscoring the need for further research to elucidate these drugs’ roles in neurodegeneration. Repurposing existing diabetes medications that have well-established safety profiles for Parkinson’s disease treatment could significantly reduce the time and cost associated with drug development and could offer a more comprehensive approach to managing Parkinson’s disease compared to treatments targeting a single mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
ORCID-Profile: Carmen Duță, Irina Stoian
Zitieren
APA
Duță, C., Muscurel, C., Dogaru, C. B., & Stoian, I. (2025). Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041516
Vancouver
Duță C, Muscurel C, Dogaru CB, Stoian I. Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041516
BibTeX
@article{Du2025,
author = {Duță, Carmen and Muscurel, Corina and Dogaru, Carmen Beatrice and Stoian, Irina},
title = {Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26041516}
}
EUVIMED